NCT04081103 - NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

February 7, 2022

Study Completion Date

February 7, 2022

Conditions

Corneal Persistent Epithelial Defect

Interventions

DRUG

Nexagon® (lufepirsen) High Dose Concentration

Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.

DRUG

Nexagon® (lufepirsen) Low Dose Concentration

Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.

DRUG

Vehicle

Vehicle is administered topically in the affected eye three (3) times over 28 days.

DRUG

Open-label Nexagon® (lufepirsen)

Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.

Trial Locations (1)

Jules Stein Eye Institute, Los Angeles